Metabogen
Metabogen is a Stockholm-based private R&D company founded in 2011 that develops microbiome-derived biomarkers and personalized treatment services. Co-founded by microbiome researcher Fredrik Bäckhed and led by CEO Sara Malcus, it operates within the Swedish microbiome research ecosystem with strategic backing from BioGaia and Vinnova.
- Company typePublic
- Founded1990
- HeadquartersStockholm, Sweden
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Metabogen does
Metabogen is a Stockholm-based R&D company founded in 2011 that is building capabilities in microbiome-derived biomarkers and personalized treatment services. The company was co-founded by Fredrik Bäckhed, a recognized microbiome researcher, and is led by CEO Sara Malcus. Metabogen's scientific positioning sits within the Swedish microbiome research ecosystem, with operational links to BioGaia's L. reuteri probiotic research platform spanning more than 35 years and 290 published clinical studies.
Metabogen's development model centers on translating microbiome and metabolomics research into biomarker signatures and personalized therapeutic applications, distinguishing it from a commercial probiotics manufacturer. Strategic validation has come through two disclosed capital events: a non-dilutive grant of approximately $596K from Vinnova in October 2017, and a strategic investment of approximately $1.39M from BioGaia in April 2018. The BioGaia investment in particular indicates alignment between Metabogen's biomarker R&D roadmap and a large affiliated probiotics franchise with distribution reach across 100 countries.
The company's commercial stage remains early and pre-revenue: no product launches, pricing, or named customer contracts are disclosed in the available data, and the cumulative disclosed capital base is approximately $2M. Metabogen operates as a private Swedish firm. The firmographic headcount band of 51-100 employees is inconsistent with the disclosed capital base and likely reflects data confusion with affiliated BioGaia records; this discrepancy should be flagged for due-diligence verification before any investment decision.
Metabogen firmographics
Firmographics- Name
- Metabogen
- Legal name
- BioGaia AB (publ)
- Website
- https://metabogen.se
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Metabogen is a Stockholm-based private R&D company founded in 2011 that develops microbiome-derived biomarkers and personalized treatment services. Co-founded by microbiome researcher Fredrik Bäckhed and led by CEO Sara Malcus, it operates within the Swedish microbiome research ecosystem with strategic backing from BioGaia and Vinnova.
- Ownership category
- akta.pro rank
Metabogen industry classification
Industry- Product category
- Microbiome Biomarker Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)
- akta.pro secondary industries
- Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Microbiome & Metagenomics Services (HLAGANAH)
Keywords
Where Metabogen is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Metabogen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Distribution channels2 records
Marketing channels3 records
Metabogen product offering
Product offeringCore offering
Metabogen operates a research and development company intended to offer biomarker and personalized treatment services, with core scientific work grounded in microbiome research and Lactobacillus reuteri (L. reuteri) strain science that has been developed for over 35 years. The company develops biomarker-based methods and personalized therapeutic approaches, leveraging one of the most scientifically documented probiotic strain libraries in the world, supported by 290+ published clinical studies. Customers are expected to be pharmaceutical, clinical, and research organizations seeking microbiome-based diagnostics and treatment stratification.
Product overview
BioGaia is a Swedish world-leading probiotics company that has been at the forefront of microbiome research for over 35 years. The company develops, manufactures, markets, and sells probiotic products across three main health areas: gut health, immune health, and oral health. The core product portfolio centers on probiotic products with strains of L. reuteri, which are among the most scientifically documented in the world with 290 published studies. The company also operates subsidiary Biogaia New Sciences AB, which has expanded into BioGaia® Skincare products for babies and children. Recent product launches include BioGaia® Protectis® Plus (next-generation probiotic baby drops) and an expanded BioGaia® Skincare portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- BioGaia Skincare: Skincare product line for babies and children developed by subsidiary Biogaia New Sciences AB, applying microbiome expertise to support healthy and balanced skin.
- BioGaia Protectis Plus
Products and services
- Biomarker Discovery Services R&D services identifying and validating microbiome-derived biomarkers intended for use in research and clinical applications by pharmaceutical, clinical, and research customers.
- Personalized Treatment Services Personalized treatment services leveraging microbiome science and Lactobacillus reuteri strain research to support patient stratification and tailored therapeutic recommendations for clinical and research partners.
Quantifiable outcome
- One out of five families globally wake up every night due to colicky babies - BioGaia Protectis Plus developed to address this
Companies that use Metabogen
Customer profileSegments2 records
Ideal customer profiles1 record
Metabogen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Metabogen partnerships and signals
Strategic signalScale indicators4 records
Recent moves3 records
Expansion highlights4 records
Metabogen competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Metabogen social profiles
Digital presenceMetabogen compliance and trust
Trust signalCompliance1 record
Metabogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Metabogen leadership team
Management profileNumber of profiles
Profiles2 records
Metabogen subsidiaries and ownership
Company hierarchySubsidiaries1 record
Metabogen funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Metabogen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Metabogen
What does Metabogen do?
Metabogen operates a research and development company intended to offer biomarker and personalized treatment services, with core scientific work grounded in microbiome research and Lactobacillus reuteri (L. reuteri) strain science that has been developed for over 35 years. The company develops biomarker-based methods and personalized therapeutic approaches, leveraging one of the most scientifically documented probiotic strain libraries in the world, supported by 290+ published clinical studies. Customers are expected to be pharmaceutical, clinical, and research organizations seeking microbiome-based diagnostics and treatment stratification.
Is Metabogen a public or private company?
Metabogen is a public company. It is classified as venture growth investor backed and is currently operating.
When was Metabogen founded?
Metabogen was founded in 1990. It employs 51 to 100 people.
Where is Metabogen based?
Metabogen is headquartered in Stockholm, Sweden, in the Europe region.
Does Metabogen have an API?
No public API is recorded for Metabogen.
What industry is Metabogen in?
Metabogen's product category is Microbiome Biomarker Services. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 8071.